Streetbeat News

Regulatory

CHRS

Coherus BioSciences, Inc. (NASDAQ:CHRS) stock is rising after announcing FDA approval for its Udenyca Onbody pegfilgrastim delivery device. The device offers an automatic delivery option for medication, complementing existing administration methods. High short interest in CHRS shares could lead to larger stock movements following such positive catalysts.

Portfolio Pulse from Erica Kollmann

December 27, 2023 | 4:54 pm

CODX

Co-Diagnostics shares are trading higher following the company's announcement of submitting its Co-Dx PCR COVID-19 test and Co-Dx PCR Pro instrument for FDA Emergency Use Authorization review.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:48 pm

AAPL

MASI

The U.S. Appeals Court has temporarily paused an import ban on certain Apple Watch models that was previously imposed. This decision comes as a relief to Apple, as the ban was related to a patent infringement case involving Masimo Corp's pulse oximetry technology. The stay on the import ban allows Apple to continue importing and selling the affected Apple Watch models while the legal proceedings continue.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:32 pm

IROHU

Trading for the IPO security IROHU was halted but has now resumed as of 10:35 AM ET.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 3:35 pm

CIFR

CLSK

HUT

Shares of Bitcoin miners Cipher Mining Inc (CIFR), CleanSpark Inc (CLSK), and Hut 8 Corp (HUT) are trading higher as Bitcoin's price rises. Bitcoin crossed $40,000 in early December and has been volatile. The crypto rally is driven by optimism for a potential spot ETF, with Grayscale refiling a Bitcoin ETF application. Analysts expect SEC approval in early 2024. Federal Reserve rate cut expectations for 2024 are also boosting the crypto market. CIFR shares rose 7.03%, CLSK 10.1%, and HUT 5.04%.

Portfolio Pulse from Adam Eckert

December 27, 2023 | 3:29 pm

NTES

NetEase shares are experiencing a downturn due to ongoing fluctuations and regulatory changes in China's gaming industry, which could affect the company's operations and market performance.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 3:16 pm

CENN

Cenntro Electric Group Limited (NASDAQ:CENN) has received the R155 and R156 EU compliance certifications, which are essential for vehicle sales in the EU starting Q2 2024. These certifications ensure that vehicles meet cybersecurity and software update standards. Cenntro's current models, LS100, LS200, and LS260, are now eligible to be sold in all EU countries, supporting the company's growth in the European market and its commitment to zero-emission initiatives.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 3:11 pm

CMPS

IXHL

PSIL

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

CHRS

CING

FWBI

HALL

IOVA

ROI

U.S. stocks saw a slight increase with the Dow Jones gaining over 20 points. Coherus BioSciences, Inc. (NASDAQ:CHRS) announced FDA approval for UDENYCA ONBODY. First Wave BioPharma, Inc. (NASDAQ:FWBI) surged 236% after announcing a term sheet to sell its Niclosamide program. Cingulate Inc. (NASDAQ:CING) and RiskOn International, Inc. (NASDAQ:ROI) also saw significant gains. Hallmark Financial Services, Inc. (NASDAQ:HALL) and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) experienced declines, with HALL intending to delist from Nasdaq and IOVA facing an FDA clinical hold.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 2:56 pm

CODX

Co-Diagnostics has submitted its Co-DX PCR COVID-19 test and Co-Dx PCR PRO instrument for FDA Emergency Use Authorization. The platform aims to support point-of-care and at-home testing, with a development pipeline including tests for TB, HPV, and a multiplex respiratory panel for flu A/B, COVID-19, and RSV.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:32 pm